Neoadjuvant T-DM1 in Early-Stage HER2+ Breast Cancer

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

Lightning Updates | 2023 Best of Breast ConferenceПодробнее

HER2 Heterogeneity and Response to Neoadjuvant T-DM1 Plus PertuzumabПодробнее

Neoadjuvant Trastuzumab and Pertuzumab Plus Chemotherapy Versus T-DM1 and Pertuzumab in HER2 BreastПодробнее

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. GradisharПодробнее

Breast Cancer Management in North Carolina: Updates for 2021 - Y. Abdou - 20210623Подробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

New Data Comparing Adjuvant T-DM1 vs Trastuzumab for HER2+ Breast CancerПодробнее

2022 West Oncology Conference | Breast Cancers | Early-StageПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Adjuvant Therapy for Early-Stage HER2-Positive Breast CancerПодробнее

Treating Early HER2+ Breast Cancer: KATHERINEПодробнее

Case 1: Approach to Early Stage, HER2+ Breast CancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

KATHERINE Trial: T-DM1 cuts HER2-positve invasive breast cancer recurrenceПодробнее

Adjuvant T-DM1 Therapy for Early-Stage HER2+ Breast CancerПодробнее

HER2+ Early-Stage Breast Cancer: Peri-Operative TherapyПодробнее

2020 Evolution | Breast Cancer Case PresentationПодробнее